If these studies find the drug to be tolerable, it would be highly interesting to extend the approach to clinical studies that combine SHP2 inhibitors with PI3K, MEK, BRAF or ALK inhibitors in breast cancer and further types of tumors which exhibit aberrations in the associated pathways. This evidence concerns the gene BRAF and breast cancer.